Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

The latest from the BIO 2025 conference: more universities open to private equity deals, emerging companies turn to new ...

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...

The average cost of a home in the capital rose 2.6% during the month from £552,402 to £566,614 according to the Land Registry ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.